Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenrispodun as Adjunctive Therapy in Parkinson's Disease
NCT05766813Phase 2Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Lenrispodun 30 mg with Placebo (2 arms). Primary endpoint: Hauser Diary at Day 29. Started Mar 2023; status: completed.
02
Drugs
lenrispodun
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05766813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766813.